

REFERENCES

Adam J. Cephalosporin. *Am. Soc. Hosp. Pharm.* 1990; 255 : 124 - 133.

Ascalone V. and Dalbo L. Determination of ceftriaxone, a novel cephalosporin, in plasma, urine and saliva by high performance liquid chromatography on an NH₂ bonded-phase column. *J. Chromatog.* 1983; 273: 357- 366.

Beskid G., Christenson J.G., Clecland R., Delorenzo W. and Trown P.W. In vivo sensitivity of ceftriaxone (Ro 13-9904), a new broad spectrum semisynthetic cephalosporin. *Antimicrob. Agents Chemother.* 1981; 4 :159-167.

Bergan T. Pharmacokinetic properties of the cephalosporins. *Drugs* (suppl.2). 1988; 34: 89-104.

Brown G.R. Pharmacokinetic drug interactions. *Clin. Pharmacokinet.* 1993; 24(4): 289-300.

Brogden R.N. and Ward A. Ceftriaxone: a reappraisal of its antibacterial activity and pharmacokinetics, and an update of the therapeutic use with particular reference to once-daily administration. *Drugs.* 1988; 35: 604-645.

- Canha B.A.. Ceftriaxone. In, *Third - generation cephalosporins*.
Canha B.A., ed, 1st ed. New Jersey: Health Communications
Press, 1985; pp. 17-19.
- Ehle I.N., Nord C.E. and Ursing B. Ceftriaxone : pharmacokinetics
and effect on the intestinal microflora in patients with acute
bacterial infections. *Scand. J. Infect Dis.* 1985; 17: 77-82.
- Esteban M.J., Canton E. and Rius F. Influence of temperature on
degradation kinetics of ceftriaxone in diluted and undiluted human
serum. *Antimicrob. Agents Chemother.* 1990; 34 (6) : 1268-
1270.
- Esteran M.J. and Canton E. Stability of ceftriaxone solution. *J.*
Antimicrob. Agents Chemother. 1992; 30: 398-399.
- Gobeaux D., Ambart L., Couderc J.L. , Renard P.H., Charnace B.D.
and Lokiec F. Ceftriaxone diffusion from blood to aqueous
humour in man. *Br.J. Ophthalmol.* 1989; 73 : 574 - 575.
- Granich G.G. and Krogstad D.J. Ion-paired high - performance liquid
chromatographic assay for ceftriaxone. *Antimicrob. Agents*
Chemother .1987; 31(3): 385-388.
- Holazo A.A., Patel I.H., Weinfeld R. and Pasonnet M. The intramus-
cular pharmacokinetics of ceftriaxone in man. *Acad. of*
Pharm. Sci. 1982; 34-38.

Jawetz E. Penicillins and cephalosporins. *In, Basic and clinical pharmacology.* Katzung B.G., Aminoff M.J., Baggot J.D., eds., 5th ed. U.S.A : Appleton and Lange, a Publishing Division of Prentice Hall, 1992; pp. 626-637.

Joos B., Luethy R., Muehlen E. and Siegenthaler W. The variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections. *Am. J. Med.* 1984; 19: 59-62.

Judson F.N. Treatment of gonorrhoea with ceftriaxone. *Sex. transmit. dis.* 1986; 13(3): 199-202.

Jungbluth G.L. and Jusko W.J. Ion - paired reversed - phase high performance liquid chromatographic assay for determination of ceftriaxone in human plasma and urine. *J. Pharm. Sci.* 1989; 78(11): 968 -970.

Kwon K.I., Bourne D.W. and Ho P.C. Effect of caffeine on the plasma protein binding and the disposition of ceftriaxone. *J. Pharm. Pharmacol.* 1985; 37 : 836 - 839.

Martin C., Ragni J., Lokiec F., Guillen J.C., Auge A., Pecking M., and Pecking M. Pharmacokinetics and tissue penetration of single dose of ceftriaxone (1,000 mg intravenous) for antibiotic prophylaxis in thoracic surgery. *Antimicrob. Agents Chemother.* 1992; 36 : 2804 - 2807.

- Meyers B.R., Srulevitch E.S., Jacobson J. and Shalom Z. Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers. *Antimicrob. Agents Chemother.* 1983; 24(5): 812-814.
- Melet M.M., Bresler L., Lokiec F., Dopft C., Boissel P. and Dureux J.B. Effects of diclofenac on ceftriaxone pharmacokinetics in human. *Antimicrob. Agents Chemother.* 1992; 36 (10): 2331-2333.
- Melet M.M., Seta N., Farinotti R. and Carbon C. Reduction of biliary excretion of ceftriaxone by diclofenac in rabbits. *Antimicrob. Agents Chemother.* 1989; 33: 1506-1510.
- Moskovitz B.L. Clinical adverse effects during ceftriaxone therapy. *Am. J. Med.* 1984; 19 : 84 - 88.
- Oda R. and Levy Y. Penetration of ceftriaxone and cefoperazone into bile and gall bladder tissue in patients with acute cholecystitis. *Dig. Dis. Sci.* 1992; 37 (11) : 1691 - 1693.
- Pesnarowski M. Bioavailability and bioequivalence. In, *Basic of Bioavailability and Description of Upjohn Single-Dose Study Design*. Chodos D.J., Disanto A.R., eds., 1st ed. Michigan: Upjohn Company, 1973; pp. 16-22.
- Paradis D., Vallee F., Allard S., Bisson C., Daviau N. and Drapeau C. et al. Comparative study of pharmacokinetics and serum

bactericidal activities of ceftiofime, ceftazidime, ceftriaxone, imipenem and ciprofloxacin. *Antimicrob. Agents Chemother.* 1992; 36(10): 2085-2090.

Patel I.H., Weinfeld R.E., Konikoff J. and Parsonnet M. Pharmacokinetics and tolerance of ceftriaxone in humans after single dose intramuscular administration in water and lidocaine diluents. *Antimicrob. Agents Chemoter.* 1982; 21 (6): 957-962.

Patel I.H., Kaplan S.A. Pharmacokinetic profile of ceftriaxone in man. *Am. J. Med.* 1984; 19 : 17 - 25.

Patel I.H., Chen S., Parsonnet M., Hackman M.R., Brooks M.A. and Konikoff J. Pharmacokinetics of ceftriaxone in human. *Antimicrob. Agents Chemoter.* 1981 ; 20 :634-641.

Richards D.M., Heel R.C., Brogden R.N., Spiegh T.M. and Avery G.S. Ceftriaxone : a review of its antibacterial activity, pharmacological properties and therapeutic use. *Drugs.* 1984; 27: 469-527.

Scully B.E., Fu K.P. and Neu H.C. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection. *Am. J. Med.* 1984; 19 : 112 - 116.

Stecle R.W., Eyre L.B., Bradsher R.W., Weinfeld R.E., Patel I.H. and Spicbandeer J. Pharmacokinetics of ceftriaxone in

pediatric patients with meningitis. *Antimicrob. Agents Chemother.* 1983; 23 (2) : 191 - 194.

Steib A., Jacobberger B., Bandel M.V., Beck F., Beller J.P. and Boudjema K. et al. Concentration in plasma and tissue penetration of ceftriaxone and ornidazole during liver transplantation. *Antimicrob. Agents Chemother.* 1993; 37 : 1873 - 1876.

Stoeckel K., Mc Namara P.J., Brandt R., Nottebrock H.P. and Ziegles W.H. Effects of concentration dependent plasma protein binding on ceftriaxone kinetics. *Clin. Pharmacol. Ther.* 1981; 29: 650 -657.

Toth A., Abdallah H.Y., Venkataramanan R., Teperman L., Halst G., and Rabinoviten M. et al. Pharmacokinetics of ceftriaxone in liver transplant recipients. *J. Clin. Pharmacol.* 1991; 31 : 722 - 728.